SCHEMBL5570070

SCHEMBL5570070

COc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1Br

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 14/20 0.85
ABCG2 Q9UNQ0 3/20 0.80
CLK1 P49759 1/20 0.80
JAK3 P52333 3/20 0.80
ABCB1 P08183 1/20 0.80
KDR P35968 7/20 0.78
LCK P06239 4/20 0.78
RET P07949 4/20 0.73
MKNK1 Q9BUB5 2/20 0.73
KIF5B P33176 2/20 0.73
ERBB2 P04626 2/20 0.71
GAK O14976 2/20 0.71
KDM4E B2RXH2 1/20 0.71
MAPK13 O15264 1/20 0.71
ABL1 P00519 1/20 0.71
CYP1A2 P05177 1/20 0.71
CDK1 P06493 1/20 0.71
CYP3A4 P08684 1/20 0.71
FBP1 P09467 1/20 0.71
CYP2D6 P10635 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5865262 0.90 EGFR (0.81) EGFRABCG2CLK1JAK3ABCB1
SCHEMBL5565137 0.89 EGFR (1.00) EGFRABCG2CLK1JAK3KDR
SCHEMBL29651 0.89 JAK3 (1.00) EGFRABCG2CLK1JAK3ABCB1
SCHEMBL29711485 0.89 JAK3 (1.00) EGFRABCG2CLK1JAK3ABCB1
SCHEMBL14095971 0.89 EGFR (0.80) EGFRABCG2CLK1JAK3ABCB1
SCHEMBL20812874 0.89 EGFR (0.80) EGFRABCG2CLK1JAK3ABCB1
SCHEMBL29372372 0.89 JAK3 (1.00) EGFRABCG2CLK1JAK3ABCB1
SCHEMBL5467825 0.88 EGFR (1.00) EGFRABCG2CLK1JAK3ABCB1
SCHEMBL6664095 0.88 EGFR (0.78) EGFRABCG2CLK1JAK3ABCB1
Hydrochloric Acid SCHEMBL5479908 0.86 EGFR (0.97) EGFRABCG2CLK1JAK3ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US claimed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP claimed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO claimed
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US disclosed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP disclosed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections IRF3, PML, TPMT EGFR 1445/4885ABCG2 311/4885CLK1 550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.